• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home StudyGraphics

#VisualAbstract: Adavosertib plus gemcitabine improves survival in platinum-resistant recurrent ovarian cancer

byConstance Wu
February 10, 2021
in StudyGraphics
Reading Time: 3 mins read
#VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression
Share on FacebookShare on TwitterShare on LinkedIn

1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus placebo.

2. Adavosertib plus gemcitabine was associated with more hematological adverse effects, such as neutropenia, versus control.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Despite advances in the field of oncology, ovarian cancer is amongst the leading causes of death from gynecological malignancies around the world. While platinum-based chemotherapy is generally considered the standard of care, recurrence and subsequent treatment resistance is common. A new approach has been to target molecules involved in the DNA damage response to overcome the resistance to platinum therapy. Both adavosertib and gemcitabine are two such molecules that have shown synergistic effects in preclinical studies of ovarian cancer. This phase 2, double-blind, randomized, controlled trial compared the use of adavosertib plus gemcitabine versus gemcitabine plus placebo in patients with platinum-resistant or refractory recurrent ovarian cancer. Overall, participants in the adavosertib plus gemcitabine group showed improvements in median progression-free and overall survival versus control. The former also showed an improved response according to the cancer antigen-125 (CA-125) criteria. In general, the adavosertib group had more adverse events than the control group; the most common grade 3 or greater adverse events included hematological events and fatigue. Grade 3-4 neutropenias and thrombocytopenias were also more common in the adavosertib group. No treatment-related deaths were recorded. A post-hoc analysis also demonstrated that patients with homologous recombination gene mutations were more likely to respond to the adavosertib plus gemcitabine combination, resulting in a nonsignificant increase in progression-free survival. A notable limitation to this study was the relatively small sample size. Because of this, the researchers were unable to implement stratification factors in their study design. This is an important concern given that, for example, BRCA mutation status is a known prognostic factor not considered in this study.

Click to read the study in The Lancet

Click to read an accompanying editorial in The Lancet

RELATED REPORTS

A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

Relevant Reading: Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.

In-Depth [randomized controlled trial]: This double-blind, randomized, placebo-controlled phase 2 trial took place in 11 academic centers in the USA and Canada, and recruited 124 women with platinum-resistant or refractory recurrent ovarian cancer. While 99 participants with high-grade serous ovarian cancer were randomized to the adavosertib plus gemcitabine or the gemcitabine plus placebo group, the other 25 participants with non-high-grade serous ovarian cancer were placed in an exploratory cohort with adavosertib and gemcitabine. The primary endpoint of this study was progression-free survival, with secondary outcomes being response rate, overall survival at 1 year, and safety/tolerability.

Overall, median progression-free survival was improved in the adavosertib group (4.6 months [95% confidence interval [CI] 3.6-6.4] vs. 3.0 months [95% CI 1.8-3.8], hazard ratio = 0.55 [95% CI 0.35-0.90]; p=0.015). Median overall survival was also improved in the adavosertib group (11.4 months [95% CI 8.2-16.5] vs. 7.2 months [95% CI 5.2-13.2], hazard ratio = 0.56 [95% CI=0.35-0.91]; p=0.017). A nonsignificant improved response by CA-125 criteria was seen in the adavosertib group (23% vs. 9%, p=0.16). The participants in the gemcitabine plus adavosertib group had more grade 3 or higher adverse events than gemcitabine with placebo. Examples include grade 3-4 neutropenia (62% with adavosertib vs. 30% with control) and thrombocytopenia (31% with adavosertib vs. 6% with control). In a post-hoc analysis, patients with homologous recombination gene mutations, such as CCNE1, had an improved response to adavosertib (Fisher’s exact test p =0.013). This was also associated with a nonsignificant increase in progression-free survival (log-rank p=0.13).

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adavosertibgemcitabineovarianovarian cancer
Previous Post

Naltrexone-bupropion treatment provides a higher response for methamphetamine use disorder

Next Post

Pregnancy outcomes in women with moderate-to-severe psoriasis

RelatedReports

Two children standing on a colorful abstract background, symbolizing growth and development, possibly related to fertility or reproductive health.
Endocrinology

A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer

October 1, 2026
A collage illustrating the urinary bladder, immune system elements, cancer cells, and an IV bag, highlighting immunotherapy for urothelial cancer.
Chronic Disease

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

September 22, 2026
Bile duct cancer collage: an engraved liver with a branching bile duct tree and gallbladder beside a surgical cap and mask
Oncology

Neoadjuvant therapy regimen improves outcomes in high-risk intrahepatic cholangiocarcinoma

March 18, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Chronic Disease

Early menarche and later menopause are associated with increased ovarian cancer risk

February 13, 2026
Next Post

Pregnancy outcomes in women with moderate-to-severe psoriasis

#VisualAbstract: Endocrine therapy plus oral S-1 improves invasive  disease-free survival in patients with ER⁺ breast cancer

#VisualAbstract: Endocrine therapy plus oral S-1 improves invasive disease-free survival in patients with ER⁺ breast cancer

Risk factors for SARS-CoV-2 seropositivity in health care workers

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
  • CDC reports 5,412 confirmed measles cases in the United States in 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.